TY - JOUR
T1 - Evaluating patient-perceived control of atopic dermatitis
T2 - design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)
AU - Pariser, David M.
AU - Simpson, Eric L.
AU - Gadkari, Abhijit
AU - Bieber, Thomas
AU - Margolis, David J.
AU - Brown, Michelle
AU - Nelson, Lauren
AU - Mahajan, Puneet
AU - Reaney, Matthew
AU - Guillemin, Isabelle
AU - Mallya, Usha G.
AU - Eckert, Laurent
N1 - Funding Information:
Medical writing support provided by Gauri Saal, MA Economics and Akua Adu-Boahene, MD, MPH Prime, Knutsford, Cheshire, UK, funded by Sanofi and Regeneron Pharmaceuticals, Inc.
Funding Information:
DMP has been a consultant to Abbott Laboratories; Amgen; Asana Biosciences, LLC; Atacama Therapeutics; Bickel Biotechnology; Biofrontera AG; Celgene Corporation; Dermira; Dermavant Sciences; DUSA Pharmaceuticals, Inc.; Eli Lilly and Company; LEO Pharma; US, Merck & Co., Inc; Novartis Pharmaceuticals Corp.; Novo Nordisk A/S; Ortho Dermatologics; Peplin, Inc.; Pfizer, Inc.; Photocure ASA; Promius Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Sanofi; Stiefel, a GSK company; TDM SurgiTech, Inc.; TheraVida; and Valeant Pharmaceuticals International. ELS has received grants/research support from Amgen, Celgene, Chugai, Galderma, and Regeneron Pharmaceuticals, Inc. and is a consultant for Anacor, Asubio, Celgene, Galderma, Genentech, Medicis, and Merck. TB was lecturer and/or consultant for Regeneron Pharmaceuticals, Inc., Sanofi, GSK, Celgene, Abbvie, AnaptysBio, Novartis, Abbvie, Asana Biosciences, LEO Pharma, Galapagos, Galderma, Kymab, Glenmark, Astellas, Daiichi-Sankyo, Eli Lilly and Company, Pfizer, Dermavant, and Allmiral. DJM has received research grants from Valeant and the National Institutes of Health for studies on atopic dermatitis and consulting monies from Valeant, Regeneron Pharmaceuticals, Inc., Sanofi, Astellas, and Anacor with respect to atopic dermatitis. MB and LN are employees of RTI Health Solutions, which received research funding for the current study. PM, MR, IG, UGM, and LE are employees and shareholders of Sanofi. AG is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Peer reviewers on this manuscript have received an honorarium from CMRO for their review work but have no other relevant financial relationships to disclose.
Publisher Copyright:
© 2019, © 2019 Sanofi Group and Regeneron Pharmaceuticals, Inc. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/3/3
Y1 - 2020/3/3
N2 - Objectives: The Atopic Dermatitis Control Tool (ADCT) was designed to evaluate patient-perceived AD control and facilitate patient–physician discussion on long-term disease control. Methods: The study was performed in adult patients with AD. Development of the ADCT followed US Food and Drug Administration (FDA) guidelines on patient-reported outcome measures (PROMs). Qualitative research, including targeted literature review, interviews with clinical experts, and combined concept elicitation/cognitive debriefing with patients with AD, was conducted to provide a list of comprehensive concepts capturing AD control per physician and patient perspectives. Quantitative methods assessed psychometric properties of the instrument and defined the threshold for AD control. Results: The resulting pilot six-item ADCT, reflecting key concepts related to AD control, had 7-day recall and assessed symptoms and impacts on patients’ everyday lives by severity and/or frequency. The ADCT showed good content validity (well understood by adult patients with AD), and quick completion time (<2 min). Psychometric analysis indicated no floor/ceiling effects for response distributions, particularly strong (r ≥ 0.80) inter-item correlations for the six ADCT items, robust construct validity (r > 0.50), and item-level discriminating ability (p <.03); this supported the derivation of a total score based on responses to all items. ADCT total score showed evidence of strong internal consistency reliability (Cronbach’s alpha >0.80). A score ≥7 points was identified as an optimum threshold to identify patients whose AD is “not in control.” Conclusions: No single validated instrument has been available to holistically evaluate patient-perceived AD control. The newly developed ADCT displays good-to-excellent content validity, construct validity, internal consistency, reliability, and discriminating ability.
AB - Objectives: The Atopic Dermatitis Control Tool (ADCT) was designed to evaluate patient-perceived AD control and facilitate patient–physician discussion on long-term disease control. Methods: The study was performed in adult patients with AD. Development of the ADCT followed US Food and Drug Administration (FDA) guidelines on patient-reported outcome measures (PROMs). Qualitative research, including targeted literature review, interviews with clinical experts, and combined concept elicitation/cognitive debriefing with patients with AD, was conducted to provide a list of comprehensive concepts capturing AD control per physician and patient perspectives. Quantitative methods assessed psychometric properties of the instrument and defined the threshold for AD control. Results: The resulting pilot six-item ADCT, reflecting key concepts related to AD control, had 7-day recall and assessed symptoms and impacts on patients’ everyday lives by severity and/or frequency. The ADCT showed good content validity (well understood by adult patients with AD), and quick completion time (<2 min). Psychometric analysis indicated no floor/ceiling effects for response distributions, particularly strong (r ≥ 0.80) inter-item correlations for the six ADCT items, robust construct validity (r > 0.50), and item-level discriminating ability (p <.03); this supported the derivation of a total score based on responses to all items. ADCT total score showed evidence of strong internal consistency reliability (Cronbach’s alpha >0.80). A score ≥7 points was identified as an optimum threshold to identify patients whose AD is “not in control.” Conclusions: No single validated instrument has been available to holistically evaluate patient-perceived AD control. The newly developed ADCT displays good-to-excellent content validity, construct validity, internal consistency, reliability, and discriminating ability.
KW - Atopic dermatitis
KW - long-term disease control
KW - patient-reported outcomes
KW - psychometric validation
UR - http://www.scopus.com/inward/record.url?scp=85076422053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076422053&partnerID=8YFLogxK
U2 - 10.1080/03007995.2019.1699516
DO - 10.1080/03007995.2019.1699516
M3 - Article
C2 - 31778083
AN - SCOPUS:85076422053
SN - 0300-7995
VL - 36
SP - 367
EP - 376
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 3
ER -